U.S. Markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    51.97
    -0.39 (-0.74%)
     
  • Gold

    1,827.90
    -2.00 (-0.11%)
     
  • Silver

    24.88
    +0.01 (+0.06%)
     
  • EUR/USD

    1.2086
    +0.0001 (+0.0121%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • Vix

    24.34
    +1.09 (+4.69%)
     
  • GBP/USD

    1.3585
    +0.0002 (+0.0122%)
     
  • USD/JPY

    103.7090
    -0.0910 (-0.0877%)
     
  • BTC-USD

    35,875.75
    +172.82 (+0.48%)
     
  • CMC Crypto 200

    698.98
    -36.16 (-4.92%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,294.15
    -225.03 (-0.79%)
     

5 Guru Stocks That Beat the Market

GuruFocus.com
·5 min read

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.

Axsome Therapeutics

Axsome Therapeutics Inc. (NASDAQ:AXSM) has a market cap of $2.11 billion. It has outperformed the S&P 500 by 312% over the past year.


aae41950e2c85b241fd7722ded50dbe4.png
aae41950e2c85b241fd7722ded50dbe4.png

Shares are trading with a price-book ratio of 11.08. As of Tuesday, the share price was 659% above the 52-week low and 47.22% below the 52-week high.

The health care service provider has a profitability rating of 1 out of 10. The return on equity of -149% and return on assets of -90% are underperforming 83% of companies in the biotechnology industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 11.03 is above the industry median of 8.24.

Chuck Royce (Trades, Portfolio) is the company's largest guru shareholder with 0.16% of outstanding shares, followed by Jim Simons (Trades, Portfolio)' Renaissance Technologies with 0.14% and Paul Tudor Jones (Trades, Portfolio) with 0.06%.

ChemoCentryx

With a market cap of $2.44 billion, ChemoCentryx Inc. (NASDAQ:CCXI) has outperformed the S&P 500 by 192% over the past 12 months.

6f138a072bf99629440b8b74250e92be.png
6f138a072bf99629440b8b74250e92be.png

Shares are trading with a price-book ratio of 34.15. As of Tuesday, the price was 545% above the 52-week low and 22.59% below the 52-week high.

The biopharmaceutical company has a profitability rating of 1 out of 10. While the return on equity of -94% is underperforming the sector, the return on assets of -25% is outperforming 61% of companies in the biotechnology industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 8.12 is below the industry median of 8.24.

The company's largest guru shareholder is Simons' firm with 1.32% of outstanding shares, followed by Joel Greenblatt (Trades, Portfolio) with 0.02%.

DexCom

Dexcom Inc. (NASDAQ:DXCM) has a market cap of $25.18 billion. It has outperformed the S&P 500 by 141% over the past year.

6fd1c8a333ad88fcbd81ac2e9ef24253.png
6fd1c8a333ad88fcbd81ac2e9ef24253.png

Shares are trading with a price-earnings ratio of 254. According to the DCF calculator, the stock is largely overpriced by 2,200% at $268. As of Tuesday, the price was 149.87% above the 52-week low and 12.47% below the 52-week high.

The company, which manufactures systems to monitor glucose level for diabetics, has a profitability rating of 3 out of 10. The return on equity of 13.78% and return on assets of 4.8% are outperforming 69% of companies in the medical diagnostics and research industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 1.32 is above the industry median of 1.31.

The company's largest guru shareholder is Steve Mandel (Trades, Portfolio) with 2.30% of outstanding shares, followed by Simons' firm with 0.76% and Ron Baron (Trades, Portfolio) with 0.56%.

Eidos Therapeutics

With a market cap of $1.88 billion, Eidos Therapeutics Inc. (NASDAQ:EIDX) has outperformed the S&P 500 by 116% over the past 12 months.

Shares are trading with a price-book ratio of 10.69. As of Tuesday, the price was 190.46% above the 52-week low and 26.38% below the 52-week high.

The biopharmaceutical company has a profitability rating of 1 out of 10. The return on equity of -24.68% and return on assets of -22.65% are outperforming 66% of companies in the biotechnology industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 8.99 is above the industry median of 8.24.

The company's largest guru shareholder is Steven Cohen (Trades, Portfolio) and Simons' firm with 0.02%.

Enphase Energy

Enphase Energy Inc. (NASDAQ:ENPH) has a market cap of $3.96 billion. It has outperformed the S&P 500 by 254% over the past 12 months.

77f2ea6a3bd38a9193ecd0d59ed6715f.png
77f2ea6a3bd38a9193ecd0d59ed6715f.png

Shares are trading with a price-earnings ratio of 26.81. According to the DCF calculator, the stock is overpriced by 143% at $32 per share. As of Tuesday, the price was 321% above the 52-week low and 42.91% below the 52-week high.

The company has a profitability rating of 2 out of 10. The return on equity of 142.94% and return on assets of 33.89% are outperforming 99% of companies in the semiconductors industry. Its financial strength is rated 7 out of 10. The cash-debt ratio of 2.31 is below the industry median of 1.38.

The company's largest guru shareholder is Simons' firm with 1.70% of outstanding shares, followed by Louis Moore Bacon (Trades, Portfolio) with 0.10% and Royce with 0.07%.

Disclosure: I do not own any of the stocks mentioned.

Read more here:

  • 5 Undervalued Stocks Trading Below Peter Lynch Value

  • 6 Banks Trading With Low Price-Sales Ratios

  • 5 High-Yielding Stocks Trading With Low Price-Earnings Ratios



Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.